Hallucinogen Use Workup
- Author: Brooke S Parish, MD; Chief Editor: Eduardo Dunayevich, MD more...
In general, laboratory studies do not play a large role in the diagnosis and treatment of hallucinogen poisoning.
- Only a few hallucinogenic agents show up on standard toxicological screens. These include MDMA (positive for amphetamines), PCP, and marijuana.
- Treatment of hallucinogen poisoning is rarely affected by drug screen results.
- Dextromethorphan (as in Robitussin DM) may cause a false-positive result for the presence of PCP.
Metabolic abnormalities should be sought and aggressively treated.
- MDMA may cause hyponatremia.
- PCP and MDMA may cause rhabdomyolysis and subsequent myoglobinuric renal failure. Check the creatine kinase level.
- Always exclude hypoglycemia as a cause of altered mental status.
A CT scan of the head is indicated in all patients with an unexplained alteration in mental status.
Erritzoe D, Frokjaer VG, Holst KK, et al. In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy") and Hallucinogen Users. Arch Gen Psychiatry. 2011 Jun. 68(6):562-76. [Medline].
de la Torre R, Farre M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci. 2004 Oct. 25(10):505-8. [Medline].
Wilcox JA, Wilcox AH. Movement disorders and MDMA abuse. J Psychoactive Drugs. 2009 Jun. 41(2):203-4. [Medline].
Kosentka P, Sprague SL, Ryberg M, Gartz J, May AL, Campagna SR, et al. Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi. PLoS One. 2013. 8(5):e64646. [Medline]. [Full Text].
US Department of Health and Human Services. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Substance Abuse and Mental Health Services Administration. Available at http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf. 2014;
SAMHSA. 2003 National Survey on Drug Use and Health. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Available at http://www.oas.samhsa.gov/nhsda/2k3nsduh/2k3Results.htm. Accessed: October 30, 2009.
Lin DL, Liu HC, Liu RH. Methylenedioxymethamphetamine-related deaths in Taiwan: 2001-2008. J Anal Toxicol. 2009 Sep. 33(7):366-71. [Medline].
Wong SS, Zhou B, Goebert D, Hishinuma ES. The risk of adolescent suicide across patterns of drug use: a nationally representative study of high school students in the United States from 1999 to 2009. Soc Psychiatry Psychiatr Epidemiol. 2013 Oct. 48(10):1611-20. [Medline].
Erowid. The Vaults of Erowid: Documenting the Complex Relationship Between Humans and Psychoactives [Web site]. [Full Text].
Greene SL, Kerr F, Braitberg G. Review article: amphetamines and related drugs of abuse. Emerg Med Australas. 2008 Oct. 20(5):391-402. [Medline].
Halpern JH, Sewell RA. Hallucinogenic botanicals of America: a growing need for focused drug education and research. Life Sci. 2005 Dec 22. 78(5):519-26. [Medline].
Ompad DC, Galea S, Fuller CM, et al. Club drug use among minority substance users in New York City. J Psychoactive Drugs. 2004 Sep. 36(3):397-9. [Medline].
Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008. 14(4):295-314. [Medline].
Prisinzano TE. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci. 2005 Dec 22. 78(5):527-31. [Medline].
SAMSHA. Ecstasy, Other Club Drugs, & Other Hallucinogens. Available at http://www.oas.samhsa.gov/ecstasy.htm.
Tucker JR, Ferm RP. Lysergic acid diethylamide and other hallucinogens. Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RS, Howland MA, Hoffman RS, eds. Goldfrank's Toxicological Emergencies. 6th ed. Stamford, Conn: Appleton & Lange; 1998. 1111-9.
Williams LC, Keyes C. Psychoactive drugs. Ford MD, Delaney KA, Ling LJ, Erickson T, eds. Clinical Toxicology. Philadelphia, Pa: WB Saunders; 2001. 640-9.